ATE408015T1 - Transfer system basierend auf einem fusionsprotein und seine anwendungen. - Google Patents

Transfer system basierend auf einem fusionsprotein und seine anwendungen.

Info

Publication number
ATE408015T1
ATE408015T1 AT96911739T AT96911739T ATE408015T1 AT E408015 T1 ATE408015 T1 AT E408015T1 AT 96911739 T AT96911739 T AT 96911739T AT 96911739 T AT96911739 T AT 96911739T AT E408015 T1 ATE408015 T1 AT E408015T1
Authority
AT
Austria
Prior art keywords
present
dna encoding
protein
lentiviral
composition
Prior art date
Application number
AT96911739T
Other languages
English (en)
Inventor
John Kappes
Xiaoyun Wu
Original Assignee
Univ Alabama Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alabama Res Found filed Critical Univ Alabama Res Found
Application granted granted Critical
Publication of ATE408015T1 publication Critical patent/ATE408015T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96911739T 1995-04-14 1996-04-12 Transfer system basierend auf einem fusionsprotein und seine anwendungen. ATE408015T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42198295A 1995-04-14 1995-04-14

Publications (1)

Publication Number Publication Date
ATE408015T1 true ATE408015T1 (de) 2008-09-15

Family

ID=23672889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911739T ATE408015T1 (de) 1995-04-14 1996-04-12 Transfer system basierend auf einem fusionsprotein und seine anwendungen.

Country Status (6)

Country Link
US (5) US6001985A (de)
EP (1) EP0873415B1 (de)
AT (1) ATE408015T1 (de)
CA (1) CA2230925C (de)
DE (1) DE69637677D1 (de)
WO (1) WO1996032494A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US20020173643A1 (en) * 1995-04-14 2002-11-21 Kappes John C. Fusion protein delivery system and uses thereof
US6087486A (en) * 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
AU2597599A (en) * 1998-02-10 1999-08-23 Uab Research Foundation, The The use of hiv-1 integrase in screening hiv-1 drug candidates
ES2291025T3 (es) 1998-05-13 2008-02-16 Genetix Pharmaceuticals Inc. Celulas lentivirales de empaquetamiento.
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US6984486B1 (en) 1999-02-19 2006-01-10 J. David Gladstone Institutes Synthetic peptide of regulatory virus protein R (VPR) of human immunodeficiency virus type 1 (HIV-1) and the utilization thereof
WO2000071726A1 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Methods to inhibit infectious agent transmission during xenotransplantation
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
JP2004532012A (ja) * 2001-03-02 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド ウイルスリポーター粒子
WO2002100317A2 (en) * 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7237559B2 (en) * 2001-08-14 2007-07-03 R.J. Reynolds Tobacco Company Wrapping materials for smoking articles
US20030167500A1 (en) * 2001-12-21 2003-09-04 Ram Ramabhadran Methods and compositions for generating a genetically modified animal using lentiviral vectors
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7402436B2 (en) * 2004-05-03 2008-07-22 City Of Hope Lentiviral vectors for site-specific gene insertion
BRPI0612951A2 (pt) * 2005-05-31 2010-12-07 Dow Global Technologies Inc Composição vedante de poliuretano e método para ligar vidro ou um plástico revestido com um revestimento resistente à abrasão a um substrato
WO2009131706A1 (en) * 2008-04-26 2009-10-29 Yung-Nien Chang Site-specific-integration lentiviral vectors
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE275259C (de) *
GB8818020D0 (en) * 1988-07-28 1988-09-01 Ici Plc Method for amplification of nucleotide sequences
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5175099A (en) * 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
ATE127520T1 (de) * 1989-06-02 1995-09-15 Dana Farber Cancer Inst Inc Protein mit transaktivierender eigenschaft, dieses protein exprimierende vektoren, zellinien und seine verwendungen.
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ATE147782T1 (de) * 1990-07-12 1997-02-15 Harvard College Primaten-lentivirus impfstoffe
US5989886A (en) 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
JPH08500965A (ja) * 1992-05-22 1996-02-06 デイナ ファーバー キャンサー インスチチュート ハイブリッドウイルス発現ベクター，その使用および新規アッセイ
WO1993025235A1 (en) * 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides
WO1994017825A1 (en) * 1993-02-05 1994-08-18 The Regents Of The University Of California Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
AU1373395A (en) * 1993-12-15 1995-07-03 Trustees Of The University Of Pennsylvania, The Vpr receptor protein
CA2186398A1 (en) * 1994-03-25 1995-10-05 Ahmed A. Azad Vpr and vpx proteins of hiv
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5639619A (en) * 1994-10-13 1997-06-17 Regents Of The University Of California Screening assay for anti-HIV drugs using the Vpr gene
US6200811B1 (en) * 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein

Also Published As

Publication number Publication date
US20040010135A1 (en) 2004-01-15
AU5482896A (en) 1996-10-30
CA2230925A1 (en) 1996-10-17
CA2230925C (en) 2010-10-12
US20020151710A1 (en) 2002-10-17
WO1996032494A1 (en) 1996-10-17
US6001985A (en) 1999-12-14
US7534603B2 (en) 2009-05-19
EP0873415A1 (de) 1998-10-28
EP0873415B1 (de) 2008-09-10
US6362000B1 (en) 2002-03-26
EP0873415A4 (de) 1999-09-08
US20030166563A1 (en) 2003-09-04
AU743113B2 (en) 2002-01-17
DE69637677D1 (de) 2008-10-23

Similar Documents

Publication Publication Date Title
DE69637677D1 (de) Transfer system basierend auf einem fusionsprotein und seine anwendungen.
DE60044754D1 (de) Trans-lentivirales Vektor System
Farnet et al. HIV-1 cDNA integration: requirement of HMG I (Y) protein for function of preintegration complexes in vitro
Sellers et al. Changing Fos oncoprotein to a Jun-independent DNA-binding protein with GCN4 dimerization specificity by swapping" leucine zippers"
Smith et al. Conserved surface-exposed K/RXK/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense
RU2225870C2 (ru) Способ разрушения клетки-мишени или инфекционного агента-мишени (варианты), химерный рецептор (варианты), днк (варианты), вектор (варианты)
Kim et al. Characterization of the nuclear export signal of human T-cell lymphotropic virus type 1 Rex reveals that nuclear export is mediated by position-variable hydrophobic interactions
Grassmann et al. In vitro binding of human T-cell leukemia virus rex proteins to the rex-response element of viral transcripts
BR9610511B1 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
DE69421624D1 (de) Medikamente bindendes protein
ES2134770T3 (es) Proteinas producidas por los linfocitos humanos, secuencia de adn codante para estas proteinas y aplicaciones farmaceuticas y biologicas.
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
BR9604993B1 (pt) dna mutante codificando uma proteìna ahas mutante de sìntese de ácido acetohidróxi e proteìnas ahas mutantes.
DE69703974D1 (de) Retrovirale vektoren
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
ATE352638T1 (de) REVERSE ßTWO-HYBRIDß-SYSTEME
Li et al. Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro
ATE380867T1 (de) Lactoferrinrezeptorgen von moraxella
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
EP1012603A4 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
Yamada et al. Proline 78 is crucial for human immunodeficiency virus type 1 Nef to down-regulate class I human leukocyte antigen
Kao et al. A novel giant secretion polypeptide in Chironomus salivary glands: implications for another Balbiani ring gene.
Chevalier et al. Presence of a functional but dispensable nuclear export signal in the HTLV-2 Tax protein
Sarojini et al. Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons
Lillehoj et al. Protein purification

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties